Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase I Study of Codrituzumab in Pediatric Patients With Relapsed or Refractory Glypican 3 (GPC3) Expressing Extra-cranial Solid Tumors

NCT04928677 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04928677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04928677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase I Study of Codrituzumab in Pediatric Patients With Relapsed or Refractory Glypican 3 (GPC3) Expressing Extra-cranial Solid Tumors
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
June 9, 2021
Completion date
June 30, 2027
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

primary extra-cranial solid tumor, recurrent or refractory glypican 3 (gpc3)